Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
Gerussi V, Petersen T, Bonnet I, Aubry A, Bachir M, Gyde E, Morel F, Poignon C, et al. (15 authors)
Emerging infectious diseases · 2025-03
Abstract
High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008-2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance. Clinicians should reconsider using high-dose isoniazid in MDR TB treatment because of suboptimal effect and toxicity concerns.
MeSH terms
- Humans
- Mycobacterium tuberculosis
- Tuberculosis, Multidrug-Resistant
- Isoniazid
- Antitubercular Agents
- Microbial Sensitivity Tests
- Drug Resistance, Multiple, Bacterial
- Adult
- Middle Aged
- France
- Female
- Male